Rallybio inks $145m Series B

New Haven, Connecticut-based Rallybio, a biopharmaceutical company, has closed $145 million in Series B funding.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to read this article and more for free.

Share this